BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 30, 2025
Home » Topics » Neurology/psychiatric, BioWorld MedTech

Neurology/psychiatric, BioWorld MedTech
Neurology/psychiatric, BioWorld MedTech RSS Feed RSS

BioWorld MedTech’s Neurology Extra for April 30, 2021

April 30, 2021
By Andrea Applegate
Keeping you up to date on recent developments in neurology, including: Detecting brain damage in babies earlier with new infrared scanner; VR treatment for PTSD to be evaluated in clinical trial; NIH study identifies diverse spectrum of neurons that govern movement.
Read More
Patient wearing Ipsihand

Neurolutions wins de novo nod for stroke rehabilitation device

April 26, 2021
By Meg Bryant
The FDA has granted de novo authorization to Neurolutions Inc. for its Ipsihand upper extremity rehabilitation system. The first-of-its kind device leverages robotics and brain-computer interface (BCI) technology to facilitate muscle training in patients with upper limb weakness or immobility following a stroke.
Read More
Patient undergoing treatment

FDA clears three-minute depression treatment with Brainsway’s Theta Burst

April 26, 2021
By Annette Boyle
Depression treatment still isn’t “once and done,” but the time needed to reduce symptoms continues to drop for patients using electromagnetic stimulation. Brainsway Ltd.’s Theta Burst brings treatment times down to just three minutes with its FDA 510(k) clearance.
Read More
Arc-Im device image

Onward corrals $32M to commercialize Arc systems for spinal cord injuries

April 23, 2021
By Annette Boyle
Onward NV secured $32 million in a new financing round led by Invest-NL and Olympic Investments. All the company’s existing investors also participated in the round, including medical technology investors LSP, Inkef Capital, Gimv, and Wellington Partners. The new funds will support Eindhoven, Netherlands-based Onward's development and commercialization of its Arc-Im and Arc-Ex spinal cord systems, designed to provide targeted spinal cord stimulation to help people with spinal cord injuries regain movement and independence.
Read More

BioWorld MedTech’s Neurology Extra for April 23, 2021

April 23, 2021
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: Fast brainwave oscillations identify, localize epileptic brain; Sleep biomarkers linked to neurodegenerative disease; Autophagy chaperone targets aggregation-prone proteins.
Read More
Bioelectronics next to penny

Feinstein team develops long-term vagus nerve stimulation model

April 21, 2021
By Annette Boyle
A team led by researchers at the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research, the research division of New York’s Northwell Health, developed a long-term implant model for vagus nerve stimulation (VNS) in mice that enables study of bioelectronics in chronic disease. The research was published in Elife, with a full description of the surgical technique and methods for calibrating the stimulation dose to enable other labs to use the methods to advance bioelectronic medicine.
Read More

BioWorld MedTech’s Neurology Extra for April 16, 2021

April 16, 2021
By Andrea Applegate
Keeping you up to date on recent developments in neurology, including: How tangled proteins kill brain cells, promote Alzheimer’s; Studies evaluate use of telemedicine with Cala Trio; Autism develops differently in girls than boys, new research suggests.
Read More
Man using Gammacore device on neck

Canadian approval of headache therapy more validation for Electrocore, new business model for RSK Medical

April 15, 2021
By David Godkin
TORONTO – For Scott Kadwell, president of Markham, Ontario-based RSK Medical Inc., the distributor tagged to sell the Health Canada approved Gammacore Sapphire, the device represents “a shift from a business to business to a direct-to-consumer business model.” For Rockaway, N.J.’s Electrocore Inc. which developed the self-administered technology, it’s one more regulator to have greenlighted the FDA cleared, CE-marked device for treating intractable migraine and cluster headache.
Read More
Close-up of eye

The eyes are the window to detecting autism and other conditions

April 14, 2021
By David Ho
HONG KONG – A professor at the Chinese University of Hong Kong (CUHK) claims that retinal eye scanning can help to improve early detection of autism and treatment outcomes for children. Benny Zee, a professor at CUHK, has developed a method to identify children at risk of autism and get them into treatment programs sooner.
Read More

BioWorld MedTech’s Neurology Extra for April 9, 2021

April 9, 2021
By Andrea Applegate
Keeping you up to date on recent developments in neurology, including: Blood test for depression, bipolar disorder developed; Specialized hydrogel helps repair circuitry in severe TBI; Using AI to diagnose neurological diseases based on motor impairment.
Read More
Previous 1 2 … 53 54 55 56 57 58 59 60 61 … 82 83 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing